A terrifying new cancer study out of Johns Hopkins Medicine confirms a suspicion some researchers have harbored all along.
A full human genome can now be sequenced for $1,000. That's still a little pricey for mass adoption, but Illumina and Pacific Biosciences could bring the cost down even further -- opening up the genomics floodgates.
What investors need to know about Pacific Biosciences' third quarter performance.
Thermo Fisher Scientific's future rests on three pillars of growth, and a big-name acquisition may tip the scales in their favor.
Illumina (ILMN) seems unbeatable in sequencing today, but tomorrow could bring changes no one can anticipate.
It's the leader in a fast-growing young industry, but does Illumina (ILMN) have what it takes to trounce the market over the long term?
Patients, doctors, and investors have been excited about new frontiers in oncology, but can these drugs be useful without companion diagnostics?
M&A's been the biggest trend of health care in 2014, but Danaher's been notably quiet. Will this acquisitions king jump into the game this year?
Illumina won rave reviews for its innovative technology after making the $1,000 genome possible, but the company showed off its financial prowess in the first quarter.
It's harder to call Illumina overpriced when it continues to surpass bullish expectations and build its lead on rivals